Argonde C van Harten1,2, Joyce Mulders3, Philip Scheltens1,2, Wiesje M van der Flier1,2,4, Cees B M Oudejans3. 1. Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands. 2. Departments of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands. 3. Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands. 4. Department of Epidemiology/Biostatistics, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND AND OBJECTIVE: The need to find a better reflection of Alzheimer's disease (AD) pathophysiology led us to investigate differential expression of microRNA (miRNA) in cerebrospinal fluid (CSF) of AD patients compared to matched controls, using a genome-wide data-driven approach. METHODS: From the Amsterdam Dementia Cohort, we selected 19 AD patients with CSF indicative of AD pathophysiology and 19 age and gender-matched controls without CSF evidence of AD (67 ± 6 years old, 20 [53%] female). We measured 754 miRNA in CSF using qRT-PCR (Taqman Array MicroRNA cards A and B, v3.0) according to the Megaplex Taqman protocol. Hierarchical cluster analysis was performed and groups were compared using Linear Models for Microarray Data, a modified t-test. We performed validation analysis using qRT-PCR single assays. RESULTS: 144 ± 66 miRNA could be detected using Megaplex array analysis (19% ). Mean Ct (average 32.4 ± 0.5) was correlated to age (r = 0.52, p = 0.001). Five miRNA were differentially expressed in CSF of AD patients. None of these could be replicated. After stratification by age, seven miRNA showed differential expression in late-onset AD, of which lower abundance of let-7a was replicated (log10RQ -1.46, p < 0.05). In early-onset AD, twelve miRNA were differentially expressed of which lower abundance of miRNA-532-3p remained borderline significant (log10RQ -1.27, p = 0.05). CONCLUSION: Although we could not consistently separate AD patients and controls in the whole group, we have found indications miRNA in CSF are able to reflect aging and perhaps also heterogeneity in AD. Further investigation requires optimizing RNA input, while maintaining strict age matching.
BACKGROUND AND OBJECTIVE: The need to find a better reflection of Alzheimer's disease (AD) pathophysiology led us to investigate differential expression of microRNA (miRNA) in cerebrospinal fluid (CSF) of ADpatients compared to matched controls, using a genome-wide data-driven approach. METHODS: From the Amsterdam Dementia Cohort, we selected 19 ADpatients with CSF indicative of AD pathophysiology and 19 age and gender-matched controls without CSF evidence of AD (67 ± 6 years old, 20 [53%] female). We measured 754 miRNA in CSF using qRT-PCR (Taqman Array MicroRNA cards A and B, v3.0) according to the Megaplex Taqman protocol. Hierarchical cluster analysis was performed and groups were compared using Linear Models for Microarray Data, a modified t-test. We performed validation analysis using qRT-PCR single assays. RESULTS: 144 ± 66 miRNA could be detected using Megaplex array analysis (19% ). Mean Ct (average 32.4 ± 0.5) was correlated to age (r = 0.52, p = 0.001). Five miRNA were differentially expressed in CSF of ADpatients. None of these could be replicated. After stratification by age, seven miRNA showed differential expression in late-onset AD, of which lower abundance of let-7a was replicated (log10RQ -1.46, p < 0.05). In early-onset AD, twelve miRNA were differentially expressed of which lower abundance of miRNA-532-3p remained borderline significant (log10RQ -1.27, p = 0.05). CONCLUSION: Although we could not consistently separate ADpatients and controls in the whole group, we have found indications miRNA in CSF are able to reflect aging and perhaps also heterogeneity in AD. Further investigation requires optimizing RNA input, while maintaining strict age matching.
Authors: Marta Cosín-Tomás; Anna Antonell; Albert Lladó; Daniel Alcolea; Juan Fortea; Mario Ezquerra; Albert Lleó; Maria José Martí; Mercè Pallàs; Raquel Sanchez-Valle; José Luís Molinuevo; Coral Sanfeliu; Perla Kaliman Journal: Mol Neurobiol Date: 2016-09-08 Impact factor: 5.590
Authors: Theresa A Lusardi; Jack T Wiedrick; Molly Malone; Jay I Phillips; Ursula S Sandau; Babett Lind; Joseph F Quinn; Jodi A Lapidus; Julie A Saugstad Journal: Mol Neurobiol Date: 2018-11-14 Impact factor: 5.590
Authors: Adrià Dangla-Valls; José Luis Molinuevo; Jordi Altirriba; Raquel Sánchez-Valle; Daniel Alcolea; Juan Fortea; Lorena Rami; Mircea Balasa; Cristina Muñoz-García; Mario Ezquerra; Rubén Fernández-Santiago; Alberto Lleó; Albert Lladó; Anna Antonell Journal: Mol Neurobiol Date: 2016-10-13 Impact factor: 5.590
Authors: Argonde C Van Harten; Heather J Wiste; Stephen D Weigand; Michelle M Mielke; Walter K Kremers; Udo Eichenlaub; Richard Batrla-Utermann; Roy B Dyer; Alicia Algeciras-Schimnich; David S Knopman; Clifford R Jack; Ronald C Petersen Journal: Neurology Date: 2020-06-26 Impact factor: 9.910
Authors: Yong-Bo Hu; Chun-Bo Li; Ning Song; Yang Zou; Sheng-Di Chen; Ru-Jing Ren; Gang Wang Journal: Front Aging Neurosci Date: 2016-02-09 Impact factor: 5.750
Authors: Ilona B Bruinsma; Marie van Dijk; Claire Bridel; Timothy van de Lisdonk; Sanne Q Haverkort; Tessel F Runia; Lawrence Steinman; Rogier Q Hintzen; Joep Killestein; Marcel M Verbeek; Charlotte E Teunissen; Brigit A de Jong Journal: J Neuroinflammation Date: 2017-12-04 Impact factor: 8.322